A South Korean court ruled this week that penalties imposed against Samsung BioLogics, parent company of biosimilar developer Samsung Bioepis, by the Financial Services Commission (FSC) for allegedly committing fraud have been suspended.
A South Korean court ruled this week that penalties imposed against Samsung BioLogics, parent company of biosimilar developer Samsung Bioepis, by the Financial Services Commission (FSC) for allegedly committing fraud have been suspended.
In November, the Nikkei Asian Review reported that the FSC had found that, in 2015, Samsung BioLogics had used accounting methods that allegedly inflated the value of the company prior to an initial public offering in 2016.
The FSC imposed penalties including an estimated $7.05 million fine, suspended Samsung BioLogics’ stock trading, and called for the firing of the firm’s chief executive officer, Kim Tae-han, as well as the chief financial officer.
The company’s stock subsequently resumed trading in December 2018 after the exchange ruled that the company’s shares could remain listed while the case played out.
Upon the alleged fraud being made public, Samsung Biologics sent a letter to its shareholders apologizing for any confusion caused by the “recent accounting issue,” and went on to say that the “[Securities and Futures Commission]’s announcement is very unfortunate as it is our firm belief that Samsung BioLogics has not breached any accounting rules at all.”
In fact, the company indicated that it had sought the advice of multiple accounting firms, all of whom deemed its accounting practices acceptable. The auditors who advised Samsung BioLogics were also sanctioned by the commission by way of fines and barring the agencies from auditing Samsung BioLogics for up to 5 years.
Samsung BioLogics then filed an administrative lawsuit at the Seoul Administrative Court seeking to nullify the commission’s findings as well as calling for an injunction to stop any disciplinary action until the court rules on the case.
“The court concluded that an immediate sanction on the company could lead to irreparable damage when its violation of accounting standards has yet to be proven in court,” said an unidentified court official, according to Reuters.
The FSC has stated that it will review the details of the courts findings and plan whether to file an immediate appeal. Samsung BioLogics, for its part, has maintained its innocence. “The court’s decision is fortunate. We will do our best to prove the legitimacy of the company’s handling of accounting,” said a Samsung BioLogics official.
Samsung now awaits the outcome of the prosecutors’ investigation.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.